Published on 16 Mar 2024 on Simply Wall St. via Yahoo Finance
US$10.00 - That's What Analysts Think ADC Therapeutics SA (NYSE:ADCT) Is Worth After These Results
There's been a notable change in appetite for ADC Therapeutics SA (NYSE:ADCT) shares in the week since its annual report, with the stock down 16% to US$3.78. It was a pretty bad result overall; while revenues were in line with expectations at US$70m, statutory losses exploded to US$2.94 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
Check out our latest analysis for ADC Therapeutics
